The treatment of brain metastases in non-small cell lung cancer (NSCLC) is a challenge, as the majority of the drugs used to treat NSCLC exhibit low penetrance to the brain. Here, Marina Garassino, MD, of the Istituto Nazionale dei Tumori, Milan, Italy, discusses the next-generation EGFR and ALK inhibitors that can be used in cases of CNS involvement. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.
Treating NSCLC with CNS involvement: TKIs with high penetrance
